{"title":"2021年获批新药迷你回顾","authors":"Akash Agnihotri, Saravana Kumar Ramasubbu","doi":"10.47363/jjcmr/2022(2)131","DOIUrl":null,"url":null,"abstract":"In 2021, the US Food and Drug Administration approved 50 novel drugs. Twenty three of the 50 (46%) drugs were categorized as orphan drug, and 9 of the 50 (18%) were approved under accelerated approval. This review includes a summary of the novel drugs approved by the US Food and Drug Administration in 2021","PeriodicalId":415591,"journal":{"name":"Japan Journal of Clinical & Medical Research","volume":"93 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"A Mini Review on New Drugs Approved in 2021\",\"authors\":\"Akash Agnihotri, Saravana Kumar Ramasubbu\",\"doi\":\"10.47363/jjcmr/2022(2)131\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In 2021, the US Food and Drug Administration approved 50 novel drugs. Twenty three of the 50 (46%) drugs were categorized as orphan drug, and 9 of the 50 (18%) were approved under accelerated approval. This review includes a summary of the novel drugs approved by the US Food and Drug Administration in 2021\",\"PeriodicalId\":415591,\"journal\":{\"name\":\"Japan Journal of Clinical & Medical Research\",\"volume\":\"93 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-04-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Japan Journal of Clinical & Medical Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.47363/jjcmr/2022(2)131\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japan Journal of Clinical & Medical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47363/jjcmr/2022(2)131","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
In 2021, the US Food and Drug Administration approved 50 novel drugs. Twenty three of the 50 (46%) drugs were categorized as orphan drug, and 9 of the 50 (18%) were approved under accelerated approval. This review includes a summary of the novel drugs approved by the US Food and Drug Administration in 2021
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
